Expansion of Ardena development and manufacturing site to aid in COVID-19 vaccine development by Novavax
Pharmaceutical CDMO Ardena (Gent, Belgium) announce the expansion of its capacity for purification and fractionation at its site in Södertälje (Sweden) to aid Novavax (MD, USA) in the long-term production of their COVID-19 vaccine.
Following conditional marketing authorization granted by the European Commission, Novavax’s COVID-19 vaccine, termed Nuvaxovid, will be the fifth vaccine approved for utilization in Europe. As a recombinant protein-based vaccine, Ardena’s expansion will satisfy Novavax’s demand for chromatographic capabilities, tangential flow filtration and lyphilization capabilities. Ardena has been a partner of Novavax for 15 years for the development of a fractionation process for Matrix-M™, a key adjuvant in Nuvaxovid to enhance immune response against the SARS-CoV-2 virus.
READ MORE ON BIOANALYSIS ZONE NOW
Submit Your Research to the F1000Research Disease Outbreaks Gateway
Contribute to the global understanding of disease outbreaks with the F1000Research Disease Outbreaks Gateway. With trusted publishing, open access, and transparent peer review, your research will uphold the highest standards of integrity while advancing knowledge in areas like COVID-19 and other public health challenges.
Join a platform that values rigor, transparency, and author control. Submit your research today at F1000Research Disease Outbreaks Gateway.
